Table 1.10
SEER Incidence and U.S. Mortality Trends by Primary Cancer Site and Sex
Blacks, 2006-2015

<table>
<thead>
<tr>
<th>Site</th>
<th>Incidence*</th>
<th>US Mortalityb</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total APC</td>
<td>Males APC</td>
</tr>
<tr>
<td>All Sites</td>
<td>-1.7*</td>
<td>-3.1*</td>
</tr>
<tr>
<td>Oral Cavity &amp; Pharynx:</td>
<td>-1.6*</td>
<td>-1.8*</td>
</tr>
<tr>
<td>Lip</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Tongue</td>
<td>-1.5*</td>
<td>-1.7</td>
</tr>
<tr>
<td>Salivary gland</td>
<td>0.4</td>
<td>0.7</td>
</tr>
<tr>
<td>Floor of mouth</td>
<td>-3.0</td>
<td>-2.3</td>
</tr>
<tr>
<td>Gum &amp; other oral cavity</td>
<td>-2.3*</td>
<td>-1.4</td>
</tr>
<tr>
<td>Nasopharynx</td>
<td>-0.7</td>
<td>-1.8</td>
</tr>
<tr>
<td>Tonsil</td>
<td>-0.5</td>
<td>-0.6</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>-3.1*</td>
<td>-3.7*</td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>-3.8*</td>
<td>-5.1*</td>
</tr>
<tr>
<td>Other oral cavity &amp; pharynx</td>
<td>-0.2</td>
<td>-0.4</td>
</tr>
<tr>
<td>Digestive System:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Esophagus</td>
<td>-4.7*</td>
<td>-5.3*</td>
</tr>
<tr>
<td>Stomach</td>
<td>-2.8*</td>
<td>-3.3*</td>
</tr>
<tr>
<td>Small intestine</td>
<td>2.3*</td>
<td>1.3</td>
</tr>
<tr>
<td>Colon &amp; Rectum:</td>
<td>-3.3*</td>
<td>-3.3*</td>
</tr>
<tr>
<td>Colon</td>
<td>-3.5*</td>
<td>-3.6*</td>
</tr>
<tr>
<td>Rectum</td>
<td>-2.7*</td>
<td>-2.5*</td>
</tr>
<tr>
<td>Anus, anal canal &amp; anorectum</td>
<td>0.8</td>
<td>1.1</td>
</tr>
<tr>
<td>Liver &amp; intrahepatic bile duct</td>
<td>2.5*</td>
<td>2.6*</td>
</tr>
<tr>
<td>Gallbladder</td>
<td>2.0*</td>
<td>0.7</td>
</tr>
<tr>
<td>Other biliary</td>
<td>-0.6</td>
<td>-0.5</td>
</tr>
<tr>
<td>Pancreas</td>
<td>-0.5</td>
<td>-0.4</td>
</tr>
<tr>
<td>Retroperitoneum</td>
<td>0.1</td>
<td>-</td>
</tr>
<tr>
<td>Peritoneum, omentum &amp; mesentery</td>
<td>-0.6</td>
<td>-</td>
</tr>
<tr>
<td>Other digestive system</td>
<td>3.6*</td>
<td>2.2</td>
</tr>
<tr>
<td>Respiratory System:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nose, nasal cavity &amp; middle ear</td>
<td>-2.6*</td>
<td>-3.4*</td>
</tr>
<tr>
<td>Larynx</td>
<td>-1.4</td>
<td>-1.8</td>
</tr>
<tr>
<td>Lung &amp; bronchus</td>
<td>-2.9*</td>
<td>-3.2*</td>
</tr>
<tr>
<td>Pleura</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Trachea &amp; other respiratory organs</td>
<td>-4.2</td>
<td>-</td>
</tr>
<tr>
<td>Bones &amp; joints</td>
<td>-1.0</td>
<td>-1.1</td>
</tr>
<tr>
<td>Soft tissue (including heart)</td>
<td>0.5</td>
<td>0.7</td>
</tr>
<tr>
<td>Skin (excl. basal &amp; squamous):</td>
<td>-0.7</td>
<td>-0.1</td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>-0.1</td>
<td>0.7</td>
</tr>
<tr>
<td>Other non-epithelial skin</td>
<td>-1.3</td>
<td>-0.8</td>
</tr>
<tr>
<td>Breast</td>
<td>0.3</td>
<td>-1.0</td>
</tr>
<tr>
<td>Breast (in situ)</td>
<td>1.1*</td>
<td>-</td>
</tr>
</tbody>
</table>

The APC is the Annual Percent Change over the time interval.
Trends are based on rates age-adjusted to the 2000 US Std Population
(19 age groups - Census P25-1130).

SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

* The APC is significantly different from zero (p<.05).
- Statistic could not be calculated. Trend based on less than 10 cases for at least one year within the time interval.
Table 1.10 - continued
SEER Incidence and U.S. Mortality Trends by Primary Cancer Site and Sex
Blacks, 2006-2015

<table>
<thead>
<tr>
<th>Site</th>
<th>Incidence*</th>
<th>US Mortalityb</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total APC</td>
<td>Males APC</td>
</tr>
<tr>
<td>Female Genital System:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervix uteri</td>
<td>0.3</td>
<td>-</td>
</tr>
<tr>
<td>Corpus uteri</td>
<td>-2.8*</td>
<td>-</td>
</tr>
<tr>
<td>Uterus, NOS</td>
<td>2.0*</td>
<td>-</td>
</tr>
<tr>
<td>Ovary</td>
<td>3.6</td>
<td>-</td>
</tr>
<tr>
<td>Vagina</td>
<td>-1.7*</td>
<td>-</td>
</tr>
<tr>
<td>Vulva</td>
<td>0.4</td>
<td>-</td>
</tr>
<tr>
<td>Other female genital system</td>
<td>5.1*</td>
<td>-</td>
</tr>
<tr>
<td>Male Genital System:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prostate</td>
<td>-5.1*</td>
<td>-</td>
</tr>
<tr>
<td>Testis</td>
<td>-5.2*</td>
<td>-</td>
</tr>
<tr>
<td>Penis</td>
<td>2.0</td>
<td>1.9</td>
</tr>
<tr>
<td>Other male genital system</td>
<td>2.0</td>
<td>-</td>
</tr>
<tr>
<td>Urinary System:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary bladder</td>
<td>0.1</td>
<td>0.0</td>
</tr>
<tr>
<td>Kidney &amp; renal pelvis</td>
<td>-0.8*</td>
<td>-</td>
</tr>
<tr>
<td>Ureter</td>
<td>0.7</td>
<td>0.7</td>
</tr>
<tr>
<td>Other urinary system</td>
<td>-5.5*</td>
<td>-</td>
</tr>
<tr>
<td>Eye &amp; Orbit</td>
<td>2.0</td>
<td>-</td>
</tr>
<tr>
<td>Brain &amp; Nervous System:</td>
<td>-0.7</td>
<td>-0.5</td>
</tr>
<tr>
<td>Cranial nerves &amp; other nervous system</td>
<td>-0.6</td>
<td>-0.9</td>
</tr>
<tr>
<td>Endocrine System:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thyroid</td>
<td>3.6*</td>
<td>1.4</td>
</tr>
<tr>
<td>Other endocrine &amp; thymus</td>
<td>4.2*</td>
<td>3.0*</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>-2.1</td>
<td>-</td>
</tr>
<tr>
<td>Hodgkin lymphoma</td>
<td>-0.3</td>
<td>-0.2</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>-0.9</td>
<td>-0.7</td>
</tr>
<tr>
<td>Myeloma</td>
<td>-0.2</td>
<td>-0.1</td>
</tr>
<tr>
<td>Leukemia</td>
<td>0.8</td>
<td>0.4</td>
</tr>
<tr>
<td>Acute lymphocytic</td>
<td>0.9</td>
<td>0.5</td>
</tr>
<tr>
<td>Chronic lymphocytic</td>
<td>0.6</td>
<td>-0.1</td>
</tr>
<tr>
<td>Other myeloid &amp; monocytic</td>
<td>-0.7</td>
<td>-3.5*</td>
</tr>
<tr>
<td>Myeloid &amp; Monocytic:</td>
<td>0.9</td>
<td>0.8</td>
</tr>
<tr>
<td>Other lymphocytic</td>
<td>-0.3</td>
<td>-</td>
</tr>
<tr>
<td>Acute myeloid</td>
<td>2.2*</td>
<td>2.2*</td>
</tr>
<tr>
<td>Chronic myeloid</td>
<td>2.9*</td>
<td>3.7*</td>
</tr>
<tr>
<td>Acute monocytic</td>
<td>1.1</td>
<td>-0.1</td>
</tr>
<tr>
<td>Chronic monocytic</td>
<td>-1.5</td>
<td>-</td>
</tr>
<tr>
<td>Other myeloid &amp; monocytic</td>
<td>-2.2</td>
<td>-</td>
</tr>
<tr>
<td>Other leukemia</td>
<td>-6.8*</td>
<td>-8.7*</td>
</tr>
<tr>
<td>Aleukemic, subleukemic &amp; NOS</td>
<td>-14.4</td>
<td>-</td>
</tr>
<tr>
<td>Kaposi Sarcoma*</td>
<td>-10.0*</td>
<td>-</td>
</tr>
<tr>
<td>Kaposi Sarcoma*</td>
<td>-0.9</td>
<td>-0.9</td>
</tr>
<tr>
<td>Mesothelioma*</td>
<td>-3.6</td>
<td>-4.7</td>
</tr>
<tr>
<td>Ill-defined &amp; unspecified</td>
<td>-3.1*</td>
<td>-3.1*</td>
</tr>
</tbody>
</table>

The APC is the Annual Percent Change over the time interval.
Trends are based on rates age-adjusted to the 2000 US Std Population
(19 age groups - Census P25-1130).

a
SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle,
Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia,
California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and
Georgia excluding ATL/RG).
b
US Mortality Files, National Center for Health Statistics, Centers for Disease Control and
Prevention.
c
Due to coding changes, Brain & Nervous System mortality are no longer shown separately.
d
Trend not shown for mortality. Category did not exist in mortality coding until 1999.
e
The APC is significantly different from zero (p<.05).
\* Statistic could not be calculated. Trend based on less than 10 cases for at least one
year within the time interval.